Adjunct targeted molecular therapy may prolong disease-free survival in patients with resected non-small cell lung cancer harbouring epidermal growth factor receptor mutations, a meta-analysis suggests.

Chinese researchers have reviewed the role of epidermal growth factor receptor tyrosine kinase inhibitors (eGFR-TKIs) after surgery for non-small cell lung cancer as the clinical value has been uncertain.

Dr Peng Xie and colleagues, from Shandong Cancer Hospital and Institute in Jinan, evaluated the agents in a meta-analysis of 11 trials covering 1152 patients recruited between 2005 and 2018.

EGFR-TKIs improved the odds of disease-free survival over that of therapies without tyrosine kinase inhibitors.